Abstract
Investigational new drug applications (INDs) for novel cell therapy products require written documentation not only of the proposed clinical protocol and specific product manufacturing process, but also of information on items that may be generic for all products manufactured within a given facility. For facilities supporting multiple IND-related protocols, this generic information can be organized into a Drug Master File (DMF). This chapter will discuss the rationale, design, maintenance, and use of a DMF, either as an official submission to the U.S. Food and Drug Administration, or as an internal reference document that compiles information for subsequent extraction and incorporation into IND submissions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
FDA Guidance for Industry: Submitting Type V Drug Master Files to the Center for Biologics Evaluation and Research, August 22, 2001.
65 Federal Register 1776 (January 12, 2000) .“New Drug Applications: Drug Master Files”: Final Rule.
FDA Guidance for Industry: Instructions and Template for Chemistry, Manufacturing, and Control (CMC) Reviewers of Human Somatic Cell Therapy Investigational New Drug Applications (INDs), August 15, 2003.
US Food and Drug Administration, Center for Biologics Evaluation and Research Guidance for FDA Review Staff and Sponsors: “Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs).” April 9, 2008.
21 Code of Federal Regulations Part 211. Current Good Manufacturing Practice for Finished Pharmaceuticals.
69 Federal Register 226 (November 24, 2004). “Current Good Tissue Practice for Human Cell, Tissue, and Cellular and Tissue-Based Product Establishments; Inspection and Enforcement”: Final Rule.
69 Federal Register 101 (May 25, 2004). “Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products”: Final Rule.
FDA Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). August 8, 2007.
21 Code of Federal Regulations Part 610. General Biological Product Standards.
FDA Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. October 22, 2004.
21 Code of Federal Regulations Part 312. Investigational New Drug Application.
Guidance for Industry: CGMP for Phase I Investigational Drugs. July 15, 2008.
AABB. Standards for Cellular Therapy Product Services. 3rd edition. AABB, Bethesda, MD, 2008.
FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration – 4th edition, October 2008.
USP 30-NF25 <1046> Cell and Gene Therapy Products. United States Pharmacopeia, Rockville, Maryland, 2007.
USP 30-NF 25 <1043> Ancillary Materials. United States Pharmacopeia, Rockville, Maryland, 2007.
FDA Guideline for Drug Master Files. September 1989 (updated March 11, 2005).
Investigational and Marketable Applications: Submission of Regulatory Documents to CBER. FDA/CBER Manual of Standard Operating Procedures and Policies. SOPP 8110, Version 1, February 6, 2003.
FDA Draft Guidance for Industry: Providing Regulatory Submissions in Electronic Format—General Considerations. October 2003.
71 Federal Register 152 (August 8, 2006). “Food and Drug Administration Electronic Submissions Gateway”: Notice.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Disclaimer: One of the authors (H.M. Khuu) is an employee of the Department of Health and Human Services of the U.S. government. The content of this chapter, however, does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Read, E., Khuu, H. (2009). Use of a Facility Master File to Facilitate Regulatory Submissions for Cell Therapy Products. In: Gee, A. (eds) Cell Therapy. Springer, Boston, MA. https://doi.org/10.1007/b102110_19
Download citation
DOI: https://doi.org/10.1007/b102110_19
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-89583-3
Online ISBN: 978-0-387-89584-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)